Bishops Stortford, UK. Dotmatics announced today that the AstraZeneca Neuroscience Innovative Medicines Unit (iMed) has selected its Cloud based informatics platform as their research data management solution. The Dotmatics platform provides a single point of access to all data and functions across multidisciplinary groups. The platform includes compound registration and tracking, biological screening, DMPK analysis, as well as a fully integrated chemistry and biology ELN and project management. This flexibility enables AstraZeneca scientists, collaborators and partners to instantly interact with the same data regardless of location and timezone, fulfilling the promise of real time research.
The AstraZeneca Neuroscience iMed’s strategy focuses on accessing cutting-edge science and world-class capabilities through partnership and collaboration with academia, industry and contract research organizations. The iMed manages a portfolio of drug discovery and development projects exclusively with external partners. Since it was created just over a year ago, the iMed has implemented innovative technologies that enable it to work seamlessly with external partners.
“We are excited to see the Dotmatics platform enabling and enriching the collaborative research capabilities of AstraZeneca’s Neuroscience iMed,” commented Dr. Stephen Gallagher, CEO of Dotmatics. “Today’s industry demands modern informatics solutions to accommodate the different ways in which people work, be it internally or externally, with CROs or partners. Our platform delivers this and, at the same time, eliminates the IT burden associated with global informatics infrastructure.”
“We were seeking an enterprise data management solution that would be comprehensive and get us up and running from day one. Dotmatics platform gives us the ability to collaborate and share data easily, securely and in real time,” said Dr. Mark Duggan, Vice President of Neuroscience iMed.
AstraZeneca Neuroscience is leading the way with its use of the Dotmatics platform for scientific data management which is a model for global externalized collaboration. The flexible nature of the Dotmatics platform delivers on the promise that scientists can easily and securely access their data at any time, from any location.
At the forefront of innovation, Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile pharmaceutical, biotechnology and chemical industries as well as academia. Dotmatics’ enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organizations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualization. Dotmatics solutions are available for local or cloud deployment and they are supported on Microsoft Windows, MAC OS X and Linux. A privately owned company, Dotmatics was founded in 2005 and their headquarters is based south of Cambridge in the UK.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.